SAN JOSE, Calif. — Erika Cheung, a key whistle-blower in the fraud trial of Elizabeth Holmes, the founder of the failed blood-testing start-up Theranos, wrapped up her testimony on Friday after saying the company had put a priority on speed over accuracy in its blood tests and answering hours of questions by the defense.
Over three days of testimony, Ms. Cheung, a former Theranos employee, detailed how some of the processes the company used to conduct its blood tests were problematic. While the defense sought to show that Theranos’s procedures were rigorous and complex, Ms. Cheung said on Friday that its priority was to conduct tests as quickly as possible and that its machines often failed their quality-control checks.
Ms. Cheung said Theranos’s blood tests might have been cheaper than other tests, but that did not mean “you should give people false information about their health status.”
Ms. Cheung was a high-profile witness for the federal government, which is trying to make the case that Ms. Holmes intentionally misled investors, doctors and patients about how well Theranos’s blood testing technology worked. The company, once held up as a Silicon Valley success story with Ms. Holmes its shining star, collapsed in 2018. Ms. Holmes, 37, faces 12 counts of wire fraud and conspiracy to commit wire fraud, and has pleaded not guilty.
Article source: https://www.nytimes.com/2021/09/17/technology/theranos-whistle-blower-erika-cheung-elizabeth-holmes.html